4579.T JPX
RaQualia Pharma Inc.
1W: +0.3%
1M: +7.6%
3M: +28.8%
YTD: -40.7%
1Y: -2.7%
3Y: -15.5%
5Y: -46.4%
¥607.00 ($3.85)
-2.00 (-0.33%)
Weekly Expected Move ±4.9%
¥550
¥579
¥609
¥639
¥668
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$10.5B
+8.9% ▲
5Y CAGR: +19.9%
Total Liabilities
$3.6B
-11.4% ▼
5Y CAGR: +72.0%
Shareholders Equity
$6.9B
+23.8% ▲
5Y CAGR: +11.4%
Cash & Investments
$3.2B
-2.9% ▼
5Y CAGR: +8.9%
Total Debt
$2.9B
-15.9% ▼
5Y CAGR: +129.6%
Net Debt
-$339M
-402.0% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $2.3B | $3.7B | $3.7B | $3.1B | $3.2B |
| Short-Term Investments | $314M | $251M | $50M | $200M | $3M |
| Cash & ST Investments | $2.7B | $3.9B | $3.8B | $3.3B | $3.2B |
| Net Receivables | $1.2B | $602M | $603M | $689M | $1.9B |
| Inventory | $11M | $8M | $148M | $168M | $160M |
| Other Current Assets | $22M | $87M | $186M | $147M | $99M |
| Total Current Assets | $4.0B | $4.8B | $5.0B | $4.5B | $5.7B |
| Property, Plant & Equip. | $299M | $391M | $574M | $529M | $436M |
| Goodwill & Intangibles | $34M | $24M | $30M | $3.9B | $3.7B |
| Long-Term Investments | $574M | $737M | $1.2B | $547M | $547M |
| Other Non-Current Assets | $9M | $1.0B | $80M | $60M | $51M |
| Total Non-Current Assets | $1.2B | $1.4B | $1.9B | $5.1B | $4.8B |
| Total Assets | $5.2B | $6.3B | $6.9B | $9.7B | $10.5B |
| — Liabilities — | |||||
| Accounts Payable | $46M | $128M | $54M | $59M | $73M |
| Short-Term Debt | $22M | $3M | $13M | $513M | $591M |
| Deferred Revenue | $294M | $0 | $0 | $0 | $147M |
| Other Current Liabilities | -$63M | $289M | $239M | $546M | $408M |
| Total Current Liabilities | $401M | $494M | $389M | $1.2B | $1.3B |
| Long-Term Debt | $0 | $9M | $39M | $2.7B | $2.1B |
| Other Non-Current Liab. | $12M | $87M | $71M | $27M | $32M |
| Total Non-Current Liabilities | $46M | $267M | $363M | $2.9B | $2.3B |
| Total Liabilities | $446M | $761M | $752M | $4.1B | $3.6B |
| — Equity — | |||||
| Common Stock | $2.3B | $2.3B | $2.7B | $2.7B | $3.2B |
| Retained Earnings | $50M | $773M | $449M | -$46M | $227M |
| Accumulated OCI | $35M | $3M | $146M | -$15M | -$3M |
| Total Stockholders Equity | $4.8B | $5.5B | $6.1B | $5.6B | $6.9B |
| Total Liabilities & Equity | $5.2B | $6.3B | $6.9B | $9.7B | $10.5B |
| — Key Metrics — | |||||
| Total Debt | $39M | $222M | $368M | $3.5B | $2.9B |
| Net Debt | -$2.3B | -$3.5B | -$3.3B | $310M | -$339M |
| Total Investments | $888M | $988M | $1.3B | $747M | $550M |